A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.

MLA

Tabernero, Josep, et al. “A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.” Cancer Research Communications, vol. 4, no. 1, Jan. 2024, pp. 28–37. EBSCOhost, https://doi.org/10.1158/2767-9764.CRC-23-0361.

APA

Tabernero, J., Yoshino, T., Stintzing, S., de Gramont, A., Gibbs, P., Jonker, D. J., Nygren, P., Papadimitriou, C., Prager, G. W., Tell, R., & Lenz, H.-J. (2024). A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. Cancer Research Communications, 4(1), 28–37. https://doi.org/10.1158/2767-9764.CRC-23-0361

Chicago

Tabernero, Josep, Takayuki Yoshino, Sebastian Stintzing, Aimery de Gramont, Peter Gibbs, Derek J Jonker, Peter Nygren, et al. 2024. “A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.” Cancer Research Communications 4 (1): 28–37. doi:10.1158/2767-9764.CRC-23-0361.